Global Animal Vaccine Market Hits $13.5 Billion in 2024 with 10.1% CAGR

Published: Feb 2026

Animal vaccine market was valued at $13.5 billion in 2024 and is projected to reach $38.7 billion by 2035, growing at a CAGR of 10.1% during the forecast period (2025-2035). The growth of the global animal vaccine market is driven by increasing demand for livestock and poultry products across developed and emerging economies. Higher consumption of meat, dairy, eggs, and aquaculture products has led producers to place greater emphasis on animal health management to maintain production levels and reduce disease-related losses. Vaccination is used as a preventive measure to control disease outbreaks, improve herd health, and support the continuity of food supply chains. As commercial farming systems expand, routine immunization practices are being adopted across cattle, poultry, swine, and aquaculture segments.

Browse the full report description of “Animal Vaccine Market Size, Share & Trends Analysis by Type (Porcine Vaccines, Poultry Vaccines, Livestock Vaccines, Aquaculture Vaccines, Companion Animal Vaccines, and Other Animal Vaccines), and by Technology (Live Attenuated Vaccines, Killed/Inactivated Vaccine, Recombinant Vaccines, and Other) Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/animal-vaccine-market

Another factor influencing market growth is the prevalence of infectious and transboundary animal diseases that affect livestock health and food security. According to the World Organisation for Animal Health (WOAH), more than 60% of known infectious diseases in humans are of animal origin, and over 75% of emerging infectious diseases are zoonotic. This has increased the implementation of vaccination programs aimed at reducing disease transmission between animal populations and humans. Vaccines are used for the management of diseases such as foot-and-mouth disease, avian influenza, and classical swine fever across multiple livestock categories.

The scale of global livestock populations and limitations in vaccination coverage also contribute to market expansion. Data published by the Food and Agriculture Organization (FAO) indicate that the global poultry population exceeds 27 billion birds, while cattle and pig populations are approximately 1.57 billion and 778 million, respectively. However, vaccination coverage remains uneven across regions. Published studies indicate that less than 17% of cattle at risk are vaccinated against foot-and-mouth disease and under 7% of pigs are vaccinated against classical swine fever. These conditions are associated with continued demand for veterinary vaccines and expansion of immunization programs.

Key Innovators Driving Animal Vaccine Market Advancement

The key players in the global animal vaccine market include Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Inc., Merck Animal Health, and Zoetis Inc., among others. These companies are engaged in the development and commercialization of veterinary vaccines for livestock and companion animals. Their activities focus on expanding disease coverage, improving vaccine efficacy, and supporting large-scale immunization programs to control infectious animal diseases.

  • In June 2025, Merck Animal Health announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines for use in dogs against leptospirosis. The vaccines are designed to provide protection against multiple leptospirosis serovars and are intended for the prevention of this bacterial disease in companion animals. Following the CVMP opinion, the products are subject to final authorization by the European Commission.
  • In February 2025, Zoetis received a conditional license from the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB), for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, for use in chickens. This conditional USDA license permits limited use of the vaccine in poultry to address highly pathogenic avian influenza (HPAI) based on demonstrated safety, purity, and reasonable expectation of efficacy.

 Market Coverage

  • The market number available for – 2024-2035
  • Base year- 2024
  • Forecast period- 2025-2035
  • Segment Covered-
    • By Type
    • By Technology 
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape - Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Inc., Merck Animal Health, and Zoetis Inc., among others.

Key questions addressed by the report.

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Animal vaccine market Report Segment

By Type

  • Porcine Vaccines
  • Poultry Vaccines
  • Livestock Vaccines
  • Aquaculture Vaccines
  • Companion Animal Vaccines
  • Other Animal Vaccines

By Technology 

  • Live Attenuated Vaccines
  • Killed/Inactivated Vaccine
  • Recombinant Vaccines
  • Other

 Animal vaccine market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/animal-vaccine-market